Fusion Antibodies (LON:FAB) Shares Down 20.3% – What’s Next?

Fusion Antibodies plc (LON:FAB)’s share price dropped 20.3% during trading on Monday . The company traded as low as GBX 9 and last traded at GBX 9.05. Approximately 2,113,557 shares traded hands during mid-day trading, an increase of 407% from the average session volume of 416,821 shares. The stock had previously closed at GBX 11.35.

Fusion Antibodies Stock Performance

The company has a debt-to-equity ratio of 92.42, a quick ratio of 2.36 and a current ratio of 1.80. The firm has a market cap of £13.91 million, a price-to-earnings ratio of -7.41 and a beta of 1.24. The stock’s fifty day moving average is GBX 10.82 and its two-hundred day moving average is GBX 12.14.

Fusion Antibodies (LON:FAB) last released its earnings results on Monday, September 14th. The company reported GBX (1.20) earnings per share for the quarter. Fusion Antibodies had a negative return on equity of 210.32% and a negative net margin of 91.92%. On average, analysts expect that Fusion Antibodies plc will post -129.9999875 earnings per share for the current fiscal year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.